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Platinum(II) complexes such as cisplatin, carboplatin and oxaliplatin are clinically approved for the
therapy of various solid tumors. Challenging pathogenic properties of cancer cells and the response of
cancers towards platinum-based drugs are strongly inﬂuenced by non-coding small RNA molecules, the
microRNAs (miRNAs). Both increased platinum activity and formation of tumor resistance towards
platinum drugs are controlled by miRNAs. This review gives an overview of the interactions between
platinum-based drugs and miRNAs, and their inﬂuence on platinum activity in various cancer types is
discussed.
© 2016 The Author. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
The platinum(II) complex cisplatin has become a salient drug in
the therapy of solid tumors since Rosenberg and coworkers have
discovered the anticancer activity of cisplatin in 1969 (Fig. 1) [1].
Cisplatin binds to DNA, i.e., its main cellular target, via coordination
to the N-7 atom of purine bases such as guanine leading to toxic
DNA cross-links [2,3]. Carboplatin and oxaliplatin feature addi-
tional anticancer drugs clinically approved in the USA and the EU
(Fig. 1) [2e4]. However, drug resistance and toxic side-effects limit
the application of these platinum complexes [3e6]. Thus, many
new platinum complexes were designed such as Pt-complex-
conjugates, trans-Pt complexes, Pt(IV) complexes, heteronuclear
complexes and N-heterocyclic carbene complexes in order to
overcome the eminent drawbacks of cisplatin, carboplatin and
oxaliplatin [7e11].
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improved therapy options. About two thousand miRNAs featuring
highly conserved non-coding RNAs of 22e23 nucleotides regulate
circa one-third of all human genes including genes involved in
signiﬁcant cellular processes such as cell proliferation, cell differ-
entiation and cell death [12,13]. MiRNAs have become valuable
tools for the establishment of prognoses for cancer patients
because of the characteristic miRNA expression patterns in tumor
tissues [14e18]. In addition, certain miRNAs regulate the survival of
drug-resistant cancer stem-like cells (CSCs) that are responsible for
relapse [19,20]. MiRNAs are also involved in the regulation of
metastasis formation, in particular, in the control of the epithelial-
to-mesenchymal transition (EMT) of cancer cells [21,22].
Inmost cases, maturemiRNAs bind to the 3'-untranslated region
(30UTR) of the target messenger RNAs (mRNAs) and, thus, inhibit
the translation of these mRNAs [23]. One miRNA species is able to
regulate various genes, and both tumor suppressor miRNAs and
oncogenic miRNAs (oncomirs) are dysregulated in various human
cancer types [24,25]. The detailed understanding of the modes of
action of miRNAs with effects on cellular cancer-related processes
is crucial for the development of improved anticancer therapies
[26e28]. A recent review published in this journal before dealt with
miRNA-modulating natural phenols and terpenoids and their ef-
fects on various tumors [29]. This review provides an overview of
widely applied anticancer active platinum complexes (cisplatin,Ai Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
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Fig. 1. Structures of the platinum(II) complexes cisplatin, carboplatin and oxaliplatin.
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2.1. Cisplatin
Cisplatin, cis-(diammine)dichloridoplatinum(II), was the ﬁrst
platinum complex that was approved for anticancer therapy by the
FDA in the USA in 1978 [30]. The chlorido ligands of the square-
planar complex cisplatin can be replaced by S- and N-bio-
nucleophiles of proteins and nucleic acids in the target cells and, in
particular, the resulting DNA damage (DNA crosslinks, e.g., 1,2-
intrastrand crosslinks) by cisplatin leads to apoptosis induction
[2,3,30]. Cisplatin is widely applied against testicular cancer, non-
small and small cell lung cancer, ovarian cancer, cervix carci-
noma, prostate carcinoma, endometrial cancer, bladder cancer,
melanoma, various sarcomas, and head-and-neck cancer [30]. It is
given to the cancer patients as intravenous chloride infusions and
the supplemented chloride salt prevents ligand exchange of
cisplatin molecules in aqueous solutions [30]. Since the main mode
of action of cisplatin is binding to DNA via guanine bases, the in-
teractions of cisplatin with miRNAs, which represent short oligo-
nucleotides, are of particular interest in order to get deeper insights
into the modes of cisplatin action in cancer cells.2.1.1. Cisplatin, miRNAs and ovarian cancer
Ovarian cancer solely affects women and features one of the
main applications of cisplatin-based therapies and the microRNA
proﬁle of cisplatin-resistant ovarian cancer cells when compared
with cisplatin-sensitive ovarian cancer cells was investigated [31].
In fact, ﬁve miRNAs (miRPlus-F1064, miR-300, miR-193b, miR-642,
miR-1299) were up-regulated while six miRNAs (let-7c, miR-20b,
miR-542-3p, miR-625, miRPlus-F1147, miRPlus-F1231) were
downregulated in the resistant ovarian cell line A2780/CP70 when
compared with the sensitive A2780 cells and was accompanied by
signiﬁcant inﬂuences on various signaling pathways (e.g., MAPK,
TGF-b, Wnt, mTOR, Notch), apoptosis, actin cytoskeleton and pro-
teasomal mechanisms [31]. Cisplatin-resistance of ovarian cancer
cells was also induced by downregulation of the tumor suppressor
let-7i [32]. Downregulated let-7i was associated with shorter PFS
(progression free survival) in late-stage ovarian cancer patients
[32]. In addition, suppression of miR-29 inhibited cisplatin-
mediated apoptosis by induction of COL1A1 (collagen type I alpha
I) in ovarian cancer cells [33]. MiR-30a sensitized ovarian cancer
cells to cisplatin treatment by suppression of ETAR (endothelin-1/
ETA receptor) and inhibition both of Akt signaling and of MAPK
(mitogen-activated protein kinase) signaling [34]. The increased
expression of miR-30c-2 sensitized cisplatin-resistant ovarian
cancer cells via inhibition of the oncoprotein Bcl-9 [35]. The ABC-Please cite this article in press as: B. Biersack, Interactions between antic
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cells which was associated with enhanced apoptosis induction by
cisplatin possibly via increased cisplatin accumulation in the cancer
cells [36]. Suppressed miR-130a levels were observed from
cisplatin-resistant ovarian cancer cells, and induced miR-130a
expression downregulated XIAP (X-linked inhibitor of apoptosis)
leading to cisplatin-sensitivity [37]. Another study of the miRNA
proﬁle of cisplatin-resistant ovarian cancer cells revealed lower
levels of let-7e, miR-30c, miR-130a, and miR-335 in the resistant
cancer cells [38]. In epithelial ovarian cancer, upregulated miR-136
augmented cisplatin-sensitivity signiﬁcantly [39]. Further to this,
the tumor suppressor miR-155 enhanced cisplatin-induced
apoptosis in SKOV3 and A2780 ovarian cancer cells by inhibition
of XIAP [40]. Both miR-152 and miR-185 were suppressed in
cisplatin-resistant ovarian cancer cells and expression of miR-152
and miR-185 overcame cisplatin resistance via suppression of
DNMT1 (DNA methyltransferase 1) [41]. EMT in EOC patients was
correlated with reduced miR-186 expression and upregulated
Twist1 transcription factor, while increased miR-186 expression
was able to revert EMT and to increase cisplatin activity in ovarian
cancer cells via suppression of Twist1 [42]. MiR-199a inhibited
mTOR (mammalian target of rapamycin) expression and signaling
in ovarian cancer cells leading cisplatin-sensitivity [43]. IGROV-1
ovarian cancer cells exhibited increased cisplatin activity due to
induced expression of miR-302b and inhibition of HDAC4 (histone
deacetylase 4) expression [44]. The tumor suppressor miR-449a
inhibited Notch-1 expression associated with promoted cisplatin
sensitivity in ovarian cancer cells [45]. Another tumor suppressor,
miR-509-3p, blocked XIAP expression and increased cisplatin-
mediated apoptosis induction in epithelial ovarian cancer cells
[46]. MiR-519d features another XIAP inhibitor expressed in ovarian
cancer cells that respond well to cisplatin treatment [47]. MiR-770-
5p was shown to target ERCC2 (excision repair cross-
complementation group 2) and, thus, blocked cisplatin resistance
formation by ovarian cancer [48]. In addition, the expression of
miR-873 blocked MDR1 (multidrug-resistance protein 1, Pgp)
expression leading to improved cisplatin response by ovarian
cancer cells and inhibition of multidrug resistance formation [49].
In contrast to that, inhibition of miR-9 sensitized ovarian cancer
cells to cisplatin treatment [50]. Expression of the oncomir miR-21
led to cisplatin resistance of ovarian cancer cells via suppressed
PDCD4 (programmed cell death protein 4) levels [51]. Its passenger
strand, miR-21-3p, also increased cisplatin resistance in various
ovarian cancer cell lines via suppression of NAV3 (neuron navigator
3) [52]. Interestingly, the natural isoquinoline alkaloid berberine
suppressed miR-21 in SKOV3 ovarian cancer cells and augmented
cisplatin activity in these cancer cells via induction of PDCD4 [53].
In platinum-resistant ovarian cancer patients, high levels of miR-
27a were discovered which was associated with poor prognosis
[54]. In addition, cisplatin-resistant ovarian cancer cells exhibited
upregulated miR-31 expression leading to the suppression of
KCNMA1 (potassium channel calcium activated large conductance
subfamily M alpha, member 1) [55]. High expression of miR-93
blocked PTEN (phosphatase and tensin homolog) expression and
inhibited cisplatin-induced apoptosis in cisplatin-resistant ovarian
cancer cells via induction of Akt-signaling [56]. Further to this, the
expression of miR-106a suppressed PDCD4 and induced cisplatin
resistance in ovarian cancer [57]. Oncogenic miR-125b mediated
cisplatin resistance in ovarian cancer cells via suppression of pro-
apoptotic Bak1 [58]. Interestingly, another group has shown that
expression of miR-130a and miR-374a reduced the activity of
cisplatin in ovarian cancer cells accompanied by increased
expression of the drug efﬂux pumps MDR1 and Pgp [59]. This is in
contrast to the previous ﬁnding that miR-130a contributed to
cisplatin-sensitivity via XIAP inhibition in ovarian cancer cells [37].ancer active platinum complexes and non-coding RNAs/microRNAs,
10.001
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reduced sensitivity to cisplatin via upregulated miR-130b which
was correlated with increased expression of MDR1, Pgp (P-glyco-
protein) and GST-p (glutathione S-transferase) [60]. In addition,
miR-141 expression was responsible for cisplatin resistance in
ovarian cancer cells via downregulation of KEAP1 (Kelch-like ECH-
associated protein 1) [61]. Omental metastases of epithelial ovarian
cancers revealed increased levels of miR-150 and miR-146a leading
to survival of ovarian cancer cells and cisplatin resistance [62].
Oncogenic miR-214 suppressed PTEN expression and activated Akt
signaling accompanied by cisplatin resistance in ovarian cancer
cells [63]. Cisplatin resistance of ovarian papillary serous carcinoma
was associated with expression of miR-224-5p leading to inhibition
of PRKCD (protein kinase C d) [64]. The expression of miR-376c
inhibited ALK7 (activin receptor-like kinase 7) expression in
epithelial ovarian cancer cells leading to cisplatin resistance [65].
Another PTEN inhibitor of ovarian cancer cells is featured by miR-
630, and suppression of miR-630 increased cisplatin activity in
epithelial ovarian carcinoma cells [66]. Recently, it was shown that
oncogenic miR-630 levels were increased after cisplatin treatment
via induction of the transcription factor E2F1 and of the miRNA-
processing Drosha protein [67]. A list of miRNAs involved in
cisplatin-resistance and esensitivity of ovarian cancers is given in
Table 1.
The processing of miRNAs into their mature form strongly de-
pends on the enzyme Dicer, and suppression of Dicer induced
chemoresistance and invasive cancer forms [68]. In particular,
knockdown of Dicer reduced the activity of cisplatin in A2780
ovarian cancer cells [68]. More recently, inhibition of the RNA-
binding protein DGCR8 (digeorge critical region 8), which pro-
cesses primary miRNA (pri-miRNA) into precursor miRNA (pre-
miRNA) together with the RNAse III Drosha in the nucleus,
enhanced the activity of cisplatin via downregulation of miR-27b
[69].
2.1.2. Cisplatin, miRNAs and lung cancer
Non-smokers are almost exclusively affected by non-small cell
lung cancer (NSCLC), while smoking patients usually suffer from
small-cell lung cancer (SCLC), and over one million people (both
men and women) die of lung cancer worldwide every year [70,71].
Platinum complexes such as cisplatin and carboplatin have become
crucial parts of chemotherapeutic treatments both of small-cell and
of non-small-cell lung cancers, and have improved the survival of
lung cancer patients signiﬁcantly when administered in combina-
tion with other anticancer drugs such as gemcitabine, etoposide,
vinorelbine or paclitaxel [70,71]. The role of miRNAs for the anti-
lung cancer activity of cisplatin was thoroughly investigated, and
the tumor suppressor miR-15a-3p enhanced the activity of cisplatin
in NSCLC cells via suppression of the anti-apoptotic Bcl-2 protein
[72]. Expression of let-7c sensitized cisplatin-resistant A549/DDP
NSCLC cells to cisplatin treatment via suppression of the ABC-
transporter ABCC2 and Bcl-xl [73]. Let-7i was suppressed in
cisplatin-resistant A549/DDP NSCLC cells as well as the long non-
coding RNA (lncRNA) AK126698 which lead to activation of the
Wnt/b-catenin signaling pathway [74]. The expression of miR-17Table 1
MicroRNA tumor suppressors and oncogenes correlated with cisplatin activity in ovarian
Tumor suppressors On
let-7c, let-7e, let-7i, miR-20b, miR-29, miR-30a, miR-30c, miR-30c-2,
miR-30d, miR-130a(!), miR-136, miR-152, miR-155, miR-185,
miR-186, miR-199a, miR-302b, miR-335, miR-449a, miR-509-3p,
miR-519d, miR-542-3p, miR-625, miR-770-5p, miR-873,
miRPlus-F1147, miRPlus-F1231
miR
miR
miR
miR
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blocked cisplatin resistance by inhibition of the TGF-b (trans-
forming growth factor) signaling pathway and repression of TGF-b
receptor 2 (TGF-bR2) [75]. Suppression of miR-17 and miR-92
families in NSCLC was correlated with cisplatin resistance via
upregulation of CDKN1A (cyclin-dependent kinase inhibitor 1A)
and of the double-strand break repair protein RAD21 leading to
efﬁcient DNA repair [76]. Downregulation of miR-26a was associ-
ated with resistance to cisplatin treatment in NSCLC cells, and
restored miR-26a expression increased cisplatin activity via inhi-
bition of HMGA2/E2F1/Akt signaling pathway and suppression of
Bcl-2 [77]. Reduced levels of miR-29b were found in NSCLC tissues
and restoredmiR-29b expression sensitized NSCLC cells to cisplatin
via downregulation of CDK6 (cyclin-dependent kinase 6), DNMT3B
and Mcl-1 (myeloid cell leukemia sequence 1) expression [78].
Restoration of miR-34a expression in lung tumors led to improved
survival of cisplatin-treated KPmice bearing lung tumors [79]. MiR-
34a-mediated suppression of PEBP4 increased cisplatin activity in
resistant lung cancer cells [80]. In addition, miR-34a sensitized
cisplatin-resistant lung cancer cells independent of their p53 ac-
tivity state and the combination of miR-34a expression with
cisplatin treatment seemed feasible [81]. Drug-resistant A549/DDP
NSCLC cells showed reduced levels of miR-135a/b associated with
cisplatin resistance via upregulation of Mcl-1 [82]. Increased levels
of miR-138 were accompanied by reduced ERCC1 expression
leading to enhanced cisplatin activity in NSCLC cells [83]. The tu-
mor suppressor miR-148b sensitized drug-resistant NSCLC cells to
cisplatin via inhibition of DNMT1 [84]. Further to this, miR-181b
expression inhibited TGF-bR1/Smad signaling leading to cisplatin
sensitivity of NSCLC cells [85]. MiR-181b also downregulated anti-
apoptotic Bcl-2 associated with increased cisplatin activity in
drug-resistant A549 NSCLC cells [86]. Expression of let-7c and miR-
200b reverted EMT in lung cancer cells and re-sensitized cancer
cells to treatment with erlotinib and cisplatin [87]. The miR-200bc/
429 cluster was downregulated in cisplatin-resistant A549/DDP
NSCLC cells associated with upregulated anti-apoptotic Bcl-2 and
XIAP, and expression of miR200bc/429 led to increased apoptosis
induction by cisplatin [88]. In SCLC cells, suppressed miR-200b
expression was observed leading to cisplatin resistance via ZEB2
(zinc-ﬁnger E-box-binding homeobox 1) [89]. In addition, expres-
sion of miR-200c restored cisplatin activity in H1266 NSCLC cells
via upregulation of E-cadherin and suppression of N-cadherin [90].
Cisplatin-mediated tumor cell growth inhibition and apoptosis
induction was promoted by expression of miR-216a in NSCLC cells
leading to suppression of eIF4B (eukaryotic initiation factor 4B) and
ZEB1 [91]. The tumor suppressor miR-217 sensitized lung cancer
cells to cisplatin treatment via KRAS (Kirsten-rat sarcoma) down-
regulation [92]. The expression of miR-375 was reduced in ERCC1-
positive NSCLC tumors associated with reduced cisplatin activity
[93]. In addition, upregulation of miR-378 sensitized cisplatin-
resistant A549/DDP and Anip973/DDP lung adenocarcinoma cells
to cisplatin treatment via suppression of secreted clusterin (sCLU)
[94]. Suppression of Akt signaling and Bcl-2 was observed from
A549 lung cancer cells expressing miR-451 which led to increased
sensitivity to cisplatin treatment [95]. NSCLC cells expressing miR-cancers.
cogenes
-9, miR-21, miR-21-3p, miR-27a, miR-27b, miR-31, miR-93, miR-106a,
-125b, miR-130a(!), miR-130b, miR-141, miR-146a, miR-150, miR-193b,
-214, miR-224-5p, miR-300, miR-374a, miR-376c, miR-630, miR-642, miR-1299,
Plus-F1064
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miR-495, and miR-495 blocked the expression of the copper
transporter ATPase ATP7A, which is involved in multidrug resis-
tance [96]. Downregulated miR-497 was observed from cisplatin-
resistant A549/DDP NSCLC cells associated with induction of anti-
apoptotic Bcl-2 protein expression [97]. Reduced expression of
miR-503 was also detected in A549/DDP NSCLC cells, and induced
miR-503 expression enhanced cisplatin activity via Bcl-2 suppres-
sion [98]. The tumor suppressor miR-509-3-5p sensitized A549
NSCLC cells to cisplatin treatment via PLK1 (polo-like kinase 1)
suppression and cell cycle arrest [99]. MiR-630 suppressed CDC7
(cell division cycle 7) kinase and augmented cisplatin activity in
A549 cells [100]. NSCLC patients expressing signiﬁcant levels of
miR-638 revealed longer survival and better response to cisplatin
chemotherapy [101].
MiR-15b induced cisplatin resistance of lung cancer cells by
downregulation of PEBP4 (phosphatidylethanolamine-binding
protein 4) [102]. The oncogenic miR-21 enhanced cisplatin resis-
tance in A549 lung cancer cells by downregulation of PTEN and
induction of anti-apoptotic Bcl-2, and miR-21 expression can be
applied as a marker for cisplatin response and survival prognoses in
NSCLC patients [103]. Suppression of oncogenic miR-25 leading to
CDC24 downregulation augmented cisplatin activity in A549 NSCLC
cells [104]. MiR-25 was also overexpressed in SCLC cells associated
with cisplatin resistance and expression of CDK2 (cyclin-dependent
kinase 2) and cyclin E2 [105]. Single nucleotide polymorphism
(SNP) in the pre-miR-27a led to increased levels of the oncogene
miR-27a associated with poorer response to cisplatin in Chinese
NSCLC patients harbouring this genetic polymorphism [106].
Expression of miR-31 blocked cisplatin-mediated apoptosis in
NSCLC cells via inhibition of the ABCB9 transporter [107]. Inhibition
of the PTEN repressor miR-92b sensitized resistant A549/DPP lung
cancer cells to cisplatin [108]. Cisplatin treatment of A549 NSCLC
cells increased p53 levels and reduced Bcl-2 and miR-98 expres-
sion, a negative regulator of p53, and upregulated miR-98 sup-
pressed p53, which is a crucial protein for cisplatin-induced
apoptosis [109]. However, there's another report about miR-98
which described cisplatin sensitivity in miR-98 expressing
A549 cells associated with increased HMGA2 levels and lowered
Bcl-2 levels [110]. ()-Epigallocatechin-3-gallate (EGCG), the major
natural catechin of the tea plant Camellia sinensis, suppressed
oncogenic miR-98-5p leading to induction of p53 expression and
increased cisplatin activity in NSCLC cells [111]. MiR-100 was
upregulated in cisplatin-resistant SCLC cells leading to suppression
of HOXA1 (homeobox A1) [112]. Both miR-106 and miR-150 func-
tioned as oncogenes in A549 lung cancer cells, and inhibition of
miR-106 and miR-150 by antisense oligonucleotides enhanced the
activity of cisplatin in these cells [113]. Increased miR-106a
expression led to cisplatin resistance in A549 NSCLC cells via sup-
pression of the ABC transporter ABCA1, which is a transporter
involved in cisplatin uptake [114]. Another oncomir, miR-128-2,
suppressed the p21-repressor E2F5 in NSCLC cells leading to inhi-
bition of apoptosis induction by cisplatin [115]. Expression of miR-
145 decreased cisplatin activity in NSCLC cells by suppression of
CDK6 [116]. In addition, suppressed miR-155 led to decreased Bax
levels and increased apoptosis induction by cisplatin in A549 NSCLCTable 2
MicroRNA tumor suppressors and oncogenes correlated with cisplatin activity in lung ca
Tumor suppressors O
let-7c, let-7i, miR-15a-3p, miR-17, miR-20a, miR-20b, miR-26a, miR-29b,
miR-34a, miR-98(!), miR-135a/b, miR-138, miR-148b, miR-181b, miR-200b,
miR-200c, miR-216a, miR-375, miR-378, miR-429, miR-451, miR-495,
miR-497, miR-503, miR-509-3-5p, miR-630, miR-638
m
m
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curcumin, a natural phenolic derivative from the roots of Curcuma
longa (turmeric), and reducedmiR-186* levels were associatedwith
augmented cisplatin activity in resistant A549/DDP NSCLC cells
[118]. Cisplatin-resistant A549/DDP cells also showed increased
levels of miR-192, and inhibition of miR-192 sensitized these lung
cancer cells to cisplatin via suppression of Bcl-2 and upregulation of
Bax [119]. MiR-205 features another PTEN repressor and miR-205
expression was associated with cisplatin resistance in NSCLC cells
[120]. Upregulated miR-224 contributed to cisplatin resistance of
lung adenocarcinoma cells via p21(WAF1/CIP1) suppression [121].
The miR-499 rs3746444T > C polymorphism was identiﬁed as a
marker for bad prognosis and cisplatin resistance in lung cancer
patients [122]. A list of miRNAs involved in cisplatin-resistance and
esensitivity of lung cancers is given in Table 2.2.1.3. Cisplatin, miRNAs and breast cancer
Among female cancer patients, breast cancer diseases represent
the major cause of death though mortality rates were reduced by
36% since 1989 [123]. The efﬁcacy of cisplatin treatment in breast
cancer patients was correlated with certain miRNA expression
proﬁles [123]. Cisplatin-resistance of breast cancer cells was
induced by downregulation of the tumor suppressor let-7i [32].
MiR-7 andmiR-345 suppressed themultidrug resistance associated
transporter MRP1 in cisplatin-resistant MCF-7/DDP breast cancer
cells [124]. In addition, miRNAs of the miR-200 family were
downregulated in cisplatin-resistant MCF-7/DDP cells [124]. MiR-
128 induced apoptosis in a p53-independent way and increased
cisplatin activity in MCF-7 breast cancer cells [125]. BRCA1 (breast
cancer 1) protein expression was induced in cisplatin-resistant
MCF-7/DDP breast cancer cells because of suppression of miR-218
and restoration of miR-218 expression sensitized these cells to
cisplatin again [126]. The expression of miR-638 was down-
regulated in breast cancer cells and induced miR-638 expression
sensitized triple-negative breast cancer cells to cisplatin treatment
[127].
Concerning oncomirs, TGF-b-induced miR-21 expression
contributed to cisplatin resistance in breast cancer cells [128]. In
linewith this ﬁnding, transfection of MCF-7 breast cancer cells with
an anti-miR-21 oligonucleotide increased cisplatin activity in these
cells [129]. In addition, cisplatin-resistant MCF-7/DDP cells showed
increased levels of oncogenic miR-10a, miR-146a, miR-221 and
miR-222, which control the expression of BRCA1 (breast cancer 1),
p27 and ERa (estrogen receptor a) [124]. MiR-221 knockdown also
induced pro-apoptotic Bim expression leading to enhanced
cisplatin activity in breast cancer cells [130]. Suppression of miR-
203 expression by anti-miR-203 increased cisplatin activity in
MCF-7 breast cancer cells by induction of SOCS3 (suppressor of
cytokine signaling 3) [131]. Overexpression of miR-569 contributed
to aggressiveness of breast tumors including increased cancer cell
survival and proliferation by downregulation of TP53INP1, and
suppression of miR-569 augmented cisplatin activity in breast
cancers [132]. A list of miRNAs involved in cisplatin-resistance and
esensitivity of breast cancers is given in Table 3.ncers.
ncogenes
iR-15b, miR-21, miR-25, miR-27a, miR-31, miR-92b, miR-98(!), miR-98-5p,
iR-100, miR-106, miR-106a, miR-128-2, miR-145, miR-150, miR-155, miR-186*,
iR-192, miR-205, miR-224, miR-499 rs3746444T > C
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Table 3
MicroRNA tumor suppressors and oncogenes correlated with cisplatin activity in breast cancers.
Tumor suppressors Oncogenes
let-7i, miR-7, miR-128, miR-200, miR-218, miR-345, miR-638 miR-10a, miR-21, miR-146a, miR-203, miR-221, miR-222, miR-569
B. Biersack / Non-coding RNA Research xxx (2016) 1e17 52.1.4. Cisplatin, miRNAs, head-and-neck cancers and esophageal
cancers
Head-and-neck cancers are mostly squamous cell carcinomas
that can affect oral (tongue), nasopharyngeal, and laryngeal parts of
the cancer patient, and head-and-neck squamous cell carcinoma
(HNSCC) is the 6th most common cancer worldwide [133]. HNSCC
is particularly prevalent in India where 30% of all cancers are
HNSCC [134,135]. Esophageal cancers represent the 8th most
common cancer worldwide and squamous cell carcinomas (ESCC)
are predominant among esophageal cancer cases as well [136].
Cisplatin-based therapies are applied for head-and-neck and
esophageal cancers though the response rate in the latter case is
only moderate (19e40%) [136e138]. Certain miRNAs can play a role
concerning the response of head-and-neck and esophageal cancers
to cisplatin. In HNSCC cells, cisplatin treatment led to suppression
of miR-181a, miR-374a, and miR-519a, while miR-630 expression
was induced [139]. Inhibition of miR-630 led to increased tumor
cell survival, while inhibition of miR-181a, miR-374a and miR-519a
reduced cell survival [139]. Nasopharyngeal carcinoma (NPC),
which is prevalent in South China and Southeast Asia, is induced by
the Epstein-Barr virus (EBV) and EBV-encoded BART Cluster 1
miRNAs reduced cisplatin activity via LMP1 suppression [140]. In-
duction of the tumor suppressor miR-16 after CDK4 knockdown in
NPC cells was associated with enhanced cisplatin activity [141].
NPC cells with EBV-encoded LMP1 (latent membrane protein 1)
induced miR-21 expression leading to inhibition of cisplatin-
induced apoptosis via downregulation of PDCD4 and Fas-L [142].
MiR-21 also reduced cisplatin activity in tongue squamous cell
carcinomas via suppression of PDCD4 [143]. Downregulation of
miR-30a in HNSCC enhanced cisplatin activity and blocked cell
motility via inhibition of Bcl-2 [144]. In addition, expression of miR-
98 in HNSCC cells enhanced cisplatin resistance by suppression of
HMGA2 (high mobility group A2) [145]. Upregulation of miR-125a
and miR-125b in cisplatin-treated NPC cells silenced cisplatin-
mediated apoptosis induction by suppression of p53 [146]. Induc-
tion of miR-101-3p in laryngeal cancer (LC) cells augmented
cisplatin resistance because miR-101-3p inhibited RIPK1 (receptor-
interacting serine/threonine kinase 1) expression [147]. Another
oncomir, miR-222, was inhibited by antisense-miR-222 in oral
squamous cell carcinoma (OSCC) cells leading to PUMA (p53
upregulated modulator of apoptosis) expression and increased
cisplatin activity [148]. In addition, expression of miR-134 in OSCC
cells increased cisplatin activity [149]. Tongue squamous cell car-
cinoma (TSCC) revealed high miR-24 expression associated with
cisplatin resistance and PTEN suppression [150]. Further to this,
TSCC tumors with suppressed miR-200c and miR-15b expression
exhibited resistance to cisplatin-based chemotherapy and poorer
prognosis of TSCC patients [151]. In contrast to that, TSCC cells with
increased miR-23a and miR-214 expression levels were cisplatin-
resistant because of suppression of TOP2B (DNA topoisomerase II
beta) [152]. Cisplatin-resistant LC cells (Hep-2/v cells) exhibited
upregulated miR-210 and miR-923 expression while miR-93 was
suppressed in the multidrug-resistant cancer cells, this miRNA
proﬁle of resistant LC cells was accompanied by suppression of
serine protease HTRA1 and NUPR1 (nuclear protein 1), and induc-
tion of RGS10 (regulator of G-protein signaling 10) expression [153].
Esophageal squamous cell carcinoma (ESCC) cells with reduced
expression of let-7b and let-7c showed cisplatin resistance andPlease cite this article in press as: B. Biersack, Interactions between antic
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cisplatin treatment via downregulation of IL-6/STAT-3 (interleukin
6/signal transducer and activator of transcription 2) signaling [154].
Induced expression of let-7g and let-7i in esophageal cancer cells
suppressed ABCC10 expression leading to increased cisplatin ac-
tivity [155]. Patients suffering from ESCC or EAC (esophagogastric
adenocarcinoma), most of them received cisplatin-based chemo-
therapies, with increased miR-21 levels exhibited shorter survival
times [156]. In addition, ESCC cells with suppressed miR-27a (via
antagomir miR-27a transfection) showed increased cisplatin ac-
tivity because of Bcl-2 inhibition and Bax induction [157]. Patho-
logic complete response (pCR) in patients suffering from
esophageal adenocarcinoma who received chemoradiation
including 5-FU (5-ﬂuorouracil) and platinum (cisplatin or oxali-
platin) therapywas correlatedwith reduced expression of miR-99b,
miR-145*, miR-451, and miR-505* [158]. The proton pump inhibitor
esomeprazole sensitized esophageal cancer cells (both ESCC and
EAC) to cisplatin treatment and revealed increased expression of
miR-141 and miR-200b as well as downregulated miR-376a levels
[159]. However, miR-141 was also described as an oncomir highly
expressed in cisplatin-resistant ESCC cells leading to YAP1 (yes-
associated protein 1) suppression [160]. EAC cells (SK-GT-4)
expressing miR-145 exhibited distinct cisplatin resistance and
promoted cancer cell invasion [161]. MiRNA polymorphisms also
play a role for cisplatin resistance and the TT genotypes of miR-
196a2 rs11614913 and miR-125a rs12976445 were associated
with reduced survival of ESCC patients receiving platinum-based
therapy (cisplatin or oxaliplatin) [162]. Cisplatin treatment of
ESCC and EAC cells exhibited changes in miRNA expression asso-
ciatedwith cell survival, threemiRNAs (miR-342-3p, miR-425, miR-
320a) were upregulated by cisplatin in ESCC cells, while two miR-
NAs (miR-548d-5p, miR-455-3p) were suppressed in EAC cells
[163]. In addition, increased expression of miR-200c was correlated
with cisplatin resistance in esophageal cancer patients via induc-
tion of Akt signaling and inhibition of PP2A (protein phosphatase
2A) [164]. MiR-330-3p features another oncomir that suppressed
PDCD4 in ESCC cells accompanied by inhibition of cisplatin-
mediated apoptosis [165]. Expression of the tumor suppressor
miR-507 augmented cisplatin activity in ESCC tumors via sup-
pression of NRF2 (NF-E2-related factor 2) [166]. Another study of
the miRNA proﬁle of cisplatin-resistant ESCC and EAC cells revealed
eleven dysregulatedmiRNAs in EAC cells (miR-191-5p andmiR-638
were upregulated, and let-7e-5p, miR-31-5p, miR-125-5p, miR-
181a-5p, miR-181b-5p, miR-200a-3p, miR-200b-3p, miR-200b-5p,
and miR-455-3p were suppressed) and one upregulated miRNA
(miR-130-3p) in ESCC cells [167]. A list of miRNAs involved in
cisplatin-resistance and esensitivity of head-and-neck cancers and
esophageal cancers is given in Table 4.2.1.5. Cisplatin, miRNAs and gastric cancers
Gastric cancer (GC) belongs to the most common cancers
worldwide (in particular, in Asia) and features the 2nd most cause
of cancer deaths [168]. Dysregulation of tumor suppressors and
oncogenes was observed from gastric cancers, including the mod-
ulation of miRNA expression in the course of carcinogenesis and
chemotherapy [169,170]. Advanced gastric cancer diseases are
commonly treated with cisplatin, however, increased toxicity and
emergence of resistance represent signiﬁcant drawbacks of thisancer active platinum complexes and non-coding RNAs/microRNAs,
0.001
Table 4
Micro-RNAs involved in cisplatin-resistance and esensitivity in head-and-neck cancers and esophageal cancers.
Sensitivity Resistance
Head-and-neck cancer miR-15b, miR-16, miR-93, miR-134, miR-200c, miR-630 BART Cluster 1 miRNAs (EBV), miR-21, miR-23a, miR-24, miR-30a,
miR-98, miR-101-3p, miR-125a, miR-125b, miR-181a, miR-210,
miR-214, miR-222, miR-374a, miR-519a, miR-923
Esophageal cancer let-7b, let-7c, let-7e-5p, let-7g, let-7i, miR-31-5p, miR-125-5p, miR-141(!),
miR-181a-5p, miR-181b-5p, miR-200a-3p, miR-200b, miR-200b-3p,
miR-200b-5p, miR-455-3p, miR-507, miR-548d-5p
miR-21, miR-27a, miR-99b, miR-125a rs12976445, miR-130-3p,
miR-141(!), miR-145, miR-145*, miR-191-5p,
miR-196a2 rs11614913, miR-200c, miR-320a, miR-330-3p,
miR-342-3p, miR-376a, miR-425, miR-451, miR-505*, miR-638
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gastric cancers was assumed. Expression of oncogenic miR-20a in
gastric cancers activated NF-kB (nuclear factor kB) signaling via
repression of NFKBIB (¼ IkBb) leading to cisplatin resistance of GC
cells [172]. In addition, miR-20a induced cisplatin resistance in GC
cells by downregulation of EGR2 (early growth response 2) [173].
Oncogenic miR-21 suppressed PTEN and induced Akt signaling
leading to cisplatin resistance of GC cells [174]. Cisplatin treatment
induced the expression of miR-29c and suppressed the oncogenic
targets of miR-29c (catenin-d and Rho signaling), which was asso-
ciated with reduced metastasis formation and lower relapse rates
in gastric cancer patients [175]. Expression of miR-30a increased
cisplatin activity in GC cells via inhibition of Snail and vimentin and
reversal of EMT [176]. In addition, expression of miR-101 enhanced
cisplatin activity in cisplatin-resistant SGC7901/DDP cells by inhi-
bition of VEGF-C (vascular endothelial growth factor C) expression
[177]. Sensitivity of GC cells to cisplatin was promoted by down-
regulation of oncogenic miR-141 and induction of the miR-141
target KEAP1, and Helicobacter pylori bacteria were able to sup-
press miR-141 in GC cells and to augment cisplatin activity [178].
However, another study on miR-141 and the long-coding RNA
(lncRNA) H19 showed that miR-141 expression downregulated the
oncogenic lncRNA H19 leading to proliferation inhibition and
increased cisplatin activity [179]. Expression of the tumor sup-
pressor miR-200c promoted cisplatin activity in resistant SGC7901/
DDP GC cells via induced expression of E-cadherin and pro-
apoptotic Bax as well as downregulation of anti-apoptotic Bcl-2
[180]. In addition, RhoE was identiﬁed as a target of miR-200c and
suppression of RhoE sensitized cisplatin-resistant GC cells to
cisplatin [181]. Expression of miR-218 in GC cells (SGC7901)
enhanced the sensitivity of these cancer cells to cisplatin treatment,
and miR-218 was induced in advanced GC patients after cytore-
ductive surgery and hyperthermic intraperitoneal chemotherapy
[182]. In contrast to that, cisplatin-resistant GC cells exhibited
increased miR-223 expression, which contributed to drug resis-
tance by downregulation of FBXW7 (F-box and WD repeat domain
containing 7) [183]. GC tissues and cells infected by H. pylori
showed upregulatedmiR-223 expression, whichmay play a role for
the emergence of cisplatin resistance in gastric cancers [183]. This is
in contrast to the observation that H. pylori suppressed miR-141
expression in GC cells associated with increased cisplatin activity
[178]. In addition, overexpression of miR-362 in GC cells (BGC-823,
SGC-7901) inhibited cisplatin-mediated apoptosis induction via
activation of NF-kB [184]. Downregulation of miR-375 contributed
to cisplatin resistance of GC cells (SGC7901/DDP) because of in-
duction of the receptor tyrosine kinase ERBB2 and activation of AktTable 5
MicroRNA tumor suppressors and oncogenes correlated with cisplatin activity in gastric
Tumor suppressors
let-7g, miR-1, miR-16, miR-29c, miR-30a, miR-34, miR-101, miR-141(!), miR-181, miR
miR-200c, miR-218, miR-342, miR-375, miR-449a, miR-503, miR-1271
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sion of miR-425 leading to PTEN suppression and cisplatin resis-
tance [186]. The tumor suppressor miR-449a inhibited Bcl-2 and
cyclin D1 expression in GC cells and, thus, enhanced cisplatin-
induced apoptosis [187]. In addition, the tumor suppressor miR-
503 inhibited Bcl-2 and IGF1R (insulin-like growth factor receptor
1) expression associated with increased apoptosis induction by
cisplatin [188]. Upregulation of miR-765 sensitized BGC-823/DDP
cells to cisplatin via inhibition of CIAPIN1 (cytokine-induced
apoptosis inhibitor 1) expression [189]. MiR-1271 expression also
sensitized GC cells to cisplatin treatment via inhibition of IGFR1,
IRS1, mTOR and Bcl-2 expression [190]. Samples of gastric cancer
patients exhibited upregulated expression of six miRNAs (let-7g,
miR-1, miR-16, miR-34, miR-181, miR-342) which were associated
with chemosensitivity to cisplatin treatment [191]. Further to this,
miR-181a blocked autophagy in GC cells and increased cisplatin
activity in SGC7901/DDP cells [192]. A list of miRNAs involved in
cisplatin activity in gastric cancers is given in Table 5.
2.1.6. Cisplatin, miRNAs, hepatomas and renal cancers
Hepatocellular carcinoma (HCC) represents the 5th most com-
mon cancer worldwide and the 3rdmost fatal cancer disease (more
than 600.000 deaths per year) [193]. Renal cell carcinoma (RCC) is
the most common kidney cancer leading to more than 13.000
deaths per year in the USA [194]. The activity of cisplatin against
both cancer types was investigated and certain miRNAs played
crucial roles for the performance of cisplatin. HCC patients who did
not respond to cisplatin-based chemotherapy exhibited twelve
upregulated miRNAs (miR-10a-1, miR-23a-1, miR-24, miR-26a,
miR-27a, miR-30c, miR-30e, miR-106b, miR-133b, miR-199a, miR-
199-3p, miR-200b) [195]. In addition, the regulation of ten miRNAs
was correlated with patient survival and cisplatin activity, i.e.,
suppression of miR-602-2 and upregulation of nine miRNAs (let-
7g-2, miR-21-2, miR-31-3, miR-98-1, miR-107-1, miR-181a-2, miR-
210-1, miR-491-1, miR-664-1) were associated with better survival
rates in HCC patients who received cisplatin treatment [195].
Expression of miR-27b enhanced cisplatin activity in HCC cells
(HepG2) by p53 activation and inhibition of CYP1B1 (cytochrome
P450 1B1) expression [196]. In contrast to that, the expression of
oncogenic miR-1180 activated NF-kB signaling in HCC cells leading
to cisplatin resistance [197]. Cisplatin-treated HCC cells showed
altered miRNA expressions (upregulated miR-34a, miR-99a and
miR-338-3p expression) which may contribute to growth inhibi-
tion and apoptosis induction by cisplatin [198]. In addition,
expression of miR-133a and miR-326 downregulated the anti-
apoptotic Bcl-xl protein which was associated with increasedcancers.
Oncogenes
-181a, miR-20a, miR-21, miR-141(!), miR-223, miR-362, miR-425
ancer active platinum complexes and non-coding RNAs/microRNAs,
10.001
Table 6
Micro-RNAs involved in cisplatin-resistance and esensitivity in hepatomas and renal cancers.
Sensitivity Resistance
Hepatoma let-7g-2, miR-21-2, miR-27b, miR-31-3, miR-34a, miR-98-1, miR-99a, miR-107-1,
miR-133a, miR-181a-2, miR-210-1, miR-326, miR-338-3p, miR-491-1, miR-664-1
miR-10a-1, miR-23a-1, miR-24, miR-26a, miR-27a, miR-30c,
miR-30e, miR-106b, miR-133b, miR-182, miR-199a, miR-199-3p,
miR-200b, miR-602-2, miR-1180
Renal cancer miR-27b miR-21
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HCC patients receiving cisplatin-based chemotherapy and it was
shown that miR-182 increased cisplatin resistance in HCC cells by
suppression of TP53INP1 (tumor protein 53-induced nuclear pro-
tein 1) expression [200].
In renal cell carcinoma cells (RCC), levels of PTENP1 (a pseu-
dogene of PTEN) were low and suppressed by oncogenic miR-21.
Increased expression of PTENP1 was accompanied by increased
cisplatin activity in RCC cells [201]. Like in HCC cells, p53 activation
and CYP1B1 suppression were observed from RCC cells expressing
miR-27b, which was associated with augmented cisplatin activity
[196]. A list of miRNAs involved in cisplatin activity in hepatomas
and renal cancers is given in Table 6.2.1.7. Cisplatin, miRNAs, bladder cancer and colon cancer
Bladder cancer is the fourth most common cancer among men
of the West, and standard chemotherapy includes cisplatin in
combination with methotrexate, vinblastine, and doxorubicin
(MVAC) or in combination with gemcitabine (GC) [202]. However,
toxicity and drug resistance feature severe drawbacks of cisplatin
therapy, which is in parts regulated bymiRNAs. Bladder cancer cells
that responded well to cisplatin treatment showed reduced levels
of miR-138 and increased expression of miR-27a and miR-642
[202]. Restored miR-27a expression in cisplatin-resistance
bladder cancer cells led to increased cisplatin activity by suppres-
sion of the cystine/glutamate exchanger SLC7A11 [203]. Cisplatin-
induced expression of miR-34a in bladder cancer cells inhibited
CD44 expression and potentiated cisplatin activity [204]. In addi-
tion, expression of miR-101 sensitized bladder cancer cells to
cisplatin treatment by suppression of COX-2 (cyclooxygenase-2)
[205]. MiR-1182 also sensitized bladder cancer cells to cisplatin via
hTERT (human telomerase reverse transcriptase) inhibition [206].
In contrast to that, miR-150 expression downregulated PDCD4 and
contributed to cisplatin resistance of muscle-invasive bladder
cancer cells [207].
Colon cancer is the 3rd most cancer worldwide and cisplatin
plays only a negligible role for the treatment of colorectal cancers
(CRC) because of inefﬁcacy and drug resistance [208]. Nevertheless,
the inﬂuence of certain miRNAs on the activity of cisplatin in colon
cancer was investigated. Expression of miR-128 in colon cancer
cells (HCT-116) increased the apoptosis induction by cisplatin in-
dependent of the p53 state via upregulation of PUMA and sup-
pression of Akt signaling [125]. In addition, expression of miR-203
sensitized colon cancer cells to cisplatin treatment via inhibition of
SIK2 (salt-inducible kinase 2) [209]. Induced expression of miR-497
by non-toxic doses of the DNA-methylation inhibitor decitabine in
HCT-116 colon cancer cells increased cisplatin activity in these
cancer cells and sensitized colon cancer stem cells to cisplatinTable 7
MicroRNA tumor suppressors and oncogenes correlated with cisplatin act
Tumor suppressors
Bladder cancer miR-27a, miR-34a, miR-101,
Colon cancer miR-128, miR-203, miR-497
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bladder cancers and colon cancers is given in Table 7.2.1.8. Cisplatin, miRNAs, cervical cancer and prostate cancer
Cervical cancer (CC) is one of the most common female cancers
with highmortality rates (ranked 2nd among female cancers) [211].
Globally, there are ca. half a million new cases and ca. 230.000
women die of this cancer per year. Most cervical cancer patients
suffer from squamous cell carcinomas (ca. 80%) while a minor
group is affected by adenocarcinomas (5e20%) [212]. Cisplatin is
applied in neoadjuvant chemotherapy of cervical cancer and this
platinum complex increased miR-34a and miR-605 expression
levels as well as p53 expression in cervical cancer samples from
cancer patients [213]. HeLa CC cells, which expressed miR-30a,
increased cisplatin-mediated apoptosis via suppression of Beclin-
1 and inhibition of autophagy [214]. In addition, expression of
miR-125a sensitized resistant CC cells to cisplatin by suppression of
STAT-3 [215]. Induction of miR-124 and miR-520b suppressed Eps8
and potentiated cisplatin activity in HeLa CC cells [216]. MiR-506
also sensitized CC cells to cisplatin via inhibition of hedgehog
signaling and suppression of Gli3 [217]. In contrast to that,
expression of miR-181a led to cisplatin resistance in CC cells by
inhibition of pro-apoptotic PRKCD (protein kinase C delta) [218].
Further to this, inhibition of miR-199a by anti-miR-199a oligonu-
cleotides augmented cisplatin activity in CC cells [219]. MiR-93 and
miR-106b contributed to cisplatin resistance in CC cells by targeting
the cell-cycle checkpoint protein RAD1 [220].
Prostate cancer (PCa) is the second most cause of death of male
cancer patients in the West [133]. PCa cells expressing miR-29b
increased apoptosis induction by cisplatin by suppression of Akt3
and DNMT3b [221]. In addition, suppression of miR-31 and miR-
205 led to cisplatin resistance by upregulation of anti-apoptotic
Bcl-w and E2F6 [222]. Inhibition of autophagy via suppression of
lysosome-associated proteins RAB27A (a Ras-related protein) and
LAMP3 (lysosomal associated membrane protein 3) by miR-205 in
castration-resistant PCa cells was accompanied by enhanced
cisplatin sensitivity in these cancer cells [223]. In contrast to that,
expression of oncogenic miR-125b mediated cisplatin resistance by
downregulation of p53, Bak1 and PUMA [224]. A list of miRNAs
involved in cisplatin activity in cervical and prostate cancers is
given in Table 8.2.1.9. Cisplatin, miRNAs and miscellaneous cancer diseases
Testicular germ cell tumors (TGCT) are the most common solid
tumors among young men and the survival rate of TGCT patients
has improvedmuch since the approval of cisplatin in the late 1970's
[30]. Nevertheless, the inﬂuence of a few miRNAs on cisplatin ac-
tivity in TGCT was investigated and the expression of miR-302aivity in bladder cancers and colon cancers.
Oncogenes
miR-642, miR-1182 miR-138, miR-150
e
ancer active platinum complexes and non-coding RNAs/microRNAs,
0.001
Table 8
MicroRNA tumor suppressors and oncogenes correlated with cisplatin activity in cervical cancers and prostate cancers.
Tumor suppressors Oncogenes
Cervical cancer miR-30a, miR-34a, miR-124, miR-125a, miR-506, miR-520b, miR-605 miR-93, miR-106b, miR-181a, miR-199a
Prostate cancer miR-29b, miR-31, miR-205 miR-125b
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p21 [225]. In addition, NT2 cells expressing miR-383 exhibited
suppressed PNUTS (a subunit of protein phosphatase 1) and histone
H2AX, which was associated with augmented cisplatin activity
[226].
Endometrial cancer (EC) represents a female malignancy with
poor prognosis. Expression of miR-134 in human EC stem cells was
downregulated leading to reduced cisplatin activity, while miR-134
expression suppressed POGLUT1 (protein O-glucosyltransferase 1)
expression and Notch signaling which was accompanied by distinct
in vivo tumor growth inhibition [227]. The inhibition of miR-200b*
in endometrioid EC cells increased the anticancer activity of
cisplatin [228]. Increased expression of miR-200b, miR-200c and
miR-429 in EC was associated with cisplatin resistance, however,
the binding site SNP rs1045385 A > C in the miRNA response
element (MRE) of the 30-UTR (30 untranslated region) of their target
gene AP-2a blocked the binding of miR-200b/200c/429 to the MRE
of AP-2a leading to upregulated expression of the tumor suppressor
AP-2a and increased cisplatin activity [229,230].
Medulloblastomas (MB) belong to the most common pediatric
neoplasms of the central nervous system [231]. Expression of miR-
34a in MB cells suppressed MAGE-A (melanoma associated anti-
gen) expression and induced p53 activity associated with enhanced
cisplatin efﬁcacy [231]. Neuroblastomas (NB) originating from the
sympathetic nervous system causes 15% of all pediatric cancer
deaths [232]. MYCN ampliﬁed high-risk NB cells expressing miR-
497 revealed downregulated cell cycle regulator WEE1, which
was accompanied by enhanced apoptosis induction by cisplatin
[232]. In addition, suppression of miR-520f in cisplatin-resistant NB
cells (SK-N-AsCis24) led to increased NAIP (neural apoptosis
inhibitory protein) expression and inhibition of cisplatin-mediated
apoptosis induction [233]. In adults, gliomas represent the most
lethal brain malignancies, and it was shown that miR-136 expres-
sion in glioma cells suppressed the E2F1 oncogene leading to
cisplatin sensitivity in glioma cells [234].
In addition, miRNAs function as key regulators in pancreatic
cancers (PaCa), and suppression of miR-374b was associated with
cisplatin resistance in pancreatic cancers [235]. In addition,
expression of miR-34 sensitized pancreatic cancer cells to cisplatin
treatment via suppression of Bcl-2 and Notch1/2 [236]. Gallbladder
cancer (GBC) is the most common cancer of the biliary tract with
poor survival rates, and it was shown that expression of miR-145
increased cisplatin activity in GBC cells via downregulation of the
multidrug resistance associated protein 1 (MRP1) [237].
In anaplastic thyroid carcinoma (ATC, a rare but aggressive
thyroid cancer), levels of the tumor suppressor miR-30d were
downregulated while induced miR-30d expression sensitized ATC
cells to cisplatin treatment by suppression of Beclin-1 and inhibi-
tion of autophagic tumor cell survival [238].
The most prevalent bone cancer is osteosarcoma (OS) and high
expression of miR-133awas associated with poor survival [239]. OS
cells treated with cisplatin showed higher levels of miR-133a, and
inhibition of miR-133a expression sensitized OS cells to cisplatin
treatment [239]. The expression of miR-103 andmiR-107 sensitized
OS cells (U2OS) to cisplatin treatment via inhibition of homologous
recombination (HR) and inhibition of the formation of RAD51 foci
[240]. In addition, U2OS cells, which expressed miR-138, showedPlease cite this article in press as: B. Biersack, Interactions between antic
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enhanced sensitivity to cisplatin treatment [241].
In order to investigate the role of Marek's Disease Virus Type 1
miRNA miR-M3 (MDV1-miR-M3) from a chicken herpes virus for
cisplatin sensitivity, chicken ﬁbroblast cells (DF-1) were transfected
withMDV1-miR-M3 [242]. The expression of MDV1-miR-M3 in DF-
1 cells inhibited cisplatin-mediated apoptosis induction via sup-
pression of Smad2 (mothers against decapentaplegic 2) [242]. A list
of miRNAs involved in cisplatin activity in miscellaneous cancers is
given in Table 9.2.2. Carboplatin
Carboplatin, cis-diammine(cyclobutane-1,1-dicarboxylate-O,O0)
platinum(II), was the second platinum complex that was approved
for anticancer therapy and it has shown reduced side-effects and
lower toxicity than cisplatin [30]. Because of its improved toxicity
proﬁle, carboplatin has begun to replace cisplatin in various solid
tumors such as ovarian cancer, lung cancer, head-and-neck cancer,
and cervix carcinomas and it is given to the patients as intravenous
infusions [30]. In the carboplatin molecule, the chlorido ligands of
cisplatin were replaced by the O,O’-chelating ligand cyclobutane-
1,1-dicarboxylate (CBDCA) which reduced the reactivity of carbo-
platin when compared with cisplatin [30]. Nevertheless, carbo-
platin formed the same DNA adducts as cisplatin and exhibited
cross-resistance to cisplatin [30].
2.2.1. Carboplatin, miRNAs and ovarian cancer
Patients who suffered from EOC (epithelial ovarian cancer) and
received carboplatin treatment were investigated for their miRNA
expression proﬁle, and high expression of miR-181-5p as well as
high phospho-Smad2 levels were associated with poor prognosis
and shorter survival [243]. The ABC-transporter ABCD2 was sup-
pressed by miR-30d in ovarian cancer cells associated with
enhanced carboplatin-mediated apoptosis induction possibly via
increased platinum accumulation in the cancer cells [36]. Reduced
miR-148b-5p expression in EOC patients who received decitabine
plus carboplatin chemotherapy exhibited shorter progression free
survival [244]. In addition, carboplatin-resistance was observed
from ovarian cancer cells that express miR-193b* leading to sup-
pression of CRIM1 (cysteine-rich transmembrane BMP regulator 1)
[245]. The expression of the miR-200 family miRNAs miR-200c and
miR-141mimics in ovarian cancer cells led to carboplatin resistance
[246]. In contrast to that, increased expression of miR-200 family
miRNAs in ovarian cancer patients who received paclitaxel-
carboplatin therapy was associated with improved response to
chemotherapy and prolonged progression free survival because of
reduction of b-tubulin III protein levels [247]. Levels of small nu-
clear RNA (snRNA) RNU2-1f (also described as miR-1246 and miR-
1290, both miRNAs are fragmented forms of RNU2-1f) was
increased in sera of EOC patients, and high RNU2-1f concentrations
were associated with carboplatin-resistance in EOC patients [248].
EOC ascites tumors exhibited upregulated miR-21 and miR-214
expression as well as carboplatin resistance [249]. High levels of
miR-27a were observed from platinum-resistant (cisplatin or car-
boplatin) ovarian cancer patients, which was associated with poor
prognosis [54]. Further to this, high levels of let-7a in ovarianancer active platinum complexes and non-coding RNAs/microRNAs,
10.001
Table 9
MicroRNA tumor suppressors and oncogenes correlated with cisplatin activity in miscellaneous cancers.
Tumor suppressors Oncogenes
miR-30d (ATC), miR-34 (PaCa), miR-34a (MB), miR-103 (OS), miR-107 (OS),
miR-134 (EC), miR-136 (glioma), miR-138 (OS), miR-145 (GBC), miR-302a (TGCT),
miR-374b (PaCa), miR-383 (TGCT), miR-497 (NB), miR-520f (NB)
miR-133a (OS), miR-200b (EC), miR-200b* (EC), miR-200c (EC), miR-429 (EC),
MDV1-miR-M3 (chicken ﬁbroblasts)
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paclitaxel-carboplatin chemotherapy and shorter survival [250]. A
list of miRNAs involved in carboplatin activity in ovarian cancers is
given in Table 10.
2.2.2. Carboplatin, miRNAs and lung cancer
NSCLC (non-small cell lung cancer) cells with high miR-19b and
lowmiR-146a expressionwere correlated with shorter survival and
lymph node metastasis promotion in NSCLC patients receiving
platinum-based chemotherapy (e.g., carboplatin) [251]. In addition,
NSCLC patients receiving platinum therapy (either carboplatin or
cisplatin) who showed partial response to platinum treatment had
low levels of oncogenic miR-21 [252]. Increased levels of the
oncogene miR-27a associated with poorer response to carboplatin
were observed from Chinese NSCLC patients who harboured a
single nucleotide polymorphism (SNP) in the pre-miR-27a [106].
NSCLC patients with increased levels of miR-135a*, miR-196b, and
miR-1290 showed improved response to platinum-based chemo-
therapy (either carboplatin or cisplatin) [253]. In A549 and H1975
lung cancer cells, expression of the tumor suppressor miR-218
inhibited tumor cell growth and invasion, while expression of
oncogenic miR-205 led to carboplatin resistance via upregulation of
anti-apoptotic Mcl-1 and survivin as well as suppression of pro-
apoptotic PARP (poly ADP ribose polymerase), caspase-3, and Bax
proteins [254]. A list of miRNAs involved in carboplatin activity in
lung cancers is given in Table 11.
2.2.3. Carboplatin, miRNAs and miscellaneous cancers
Carboplatin-resistant Huh-7 hepatocellular carcinoma (HCC)
cells showed increased expression of miR-27b, miR-146a, miR-
146b-5p, miR-181a, and miR-181d [255]. In contrast to that, the
expression of miR-621 in breast cancer cells sensitized these cancer
cells to carboplatin treatment via inhibition of FBXO11 and
increased p53 activity [256]. In addition, increased expression of
miR-218 in cervical cancer (CC) cells augmented carboplatin ac-
tivity via suppression of cyclin D1 followed by cell cycle arrest
[257]. In retinoblastoma (RB) cells, miR-34a inhibited HMGB1
expression leading to enhanced activity of chemotherapeutic
agents including carboplatin [258]. A list of miRNAs involved in
carboplatin activity in miscellaneous cancers is given in Table 12.
2.3. Oxaliplatin
Oxaliplatin differs structurally from cisplatin and carboplatin,
and this Pt(II) complex consists of an N,N’-chelating ligand (trans-
1R,2R-diaminocyclohexane, DACH) and the O,O’-chelating ligand
oxalate [30]. Due to the bulky organic DACH ligand of oxaliplatin,
the DNA adducts built by oxaliplatin were more toxic when
compared with cisplatin adducts and the oxaliplatin-DNA-adducts
were not recognized by the DNA mismatch repair system [30].Table 10
MicroRNA tumor suppressors and oncogenes correlated with carboplatin activity in ovar
Tumor suppressors Oncogenes
miR-30d, miR-148b-5p, miR-200 family(!) let-7a, miR-21, miR-27a, miR-141
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in colorectal cancers (CRC) which are resistant to cisplatin and
carboplatin treatment [30]. Consequently, oxaliplatinwas approved
for the treatment of colorectal cancers and is mostly given as
intravenous infusions in combination with 5-FU and folinate (¼
FOLFOX regimen) [30].2.3.1. Oxaliplatin, miRNAs and colorectal cancers
Treatment of CRC (colorectal cancer) cells (HCT-8) with oxali-
platin led to suppression of six oncogenic miRNAs (miR-92a, miR-
93, miR-191, miR-197, miR-222, miR-1826) which likely contrib-
uted to the potent oxaliplatin activity against CRC [259]. In contrast
to that, oxaliplatin-resistant CRC cells showed upregulatedmiR-203
expression via inhibition of ATM kinase expression [260]. MiR-153
expression also led to oxaliplatin resistance by downregulation of
FOXO3a (forkhead box O3a) [261]. High levels of miR-20a were
found in oxaliplatin-resistant SW620 CRC cells leading to BNIP2
(Bcl-2/adenovirus E1B 19 kDa interacting protein 2) targeting, and
inhibition of miR-20a sensitized SW620 cells to oxaliplatin treat-
ment [262]. It was found that deregulated stromal cells produced
oncogenic miR-21 leading to inhibition of oxaliplatin-mediated
apoptosis induction in CRC cells and to enhanced invasiveness of
CRC cells via suppression of the MMP2 (matrix metalloproteinase
2) inhibitor RECK (reversion-inducing cysteine-rich protein motif
with Kazal motifs) [263]. The biguanide metformin suppressed
miR-21 expression in CRC cells via inhibition of Wnt signaling
leading to increased oxaliplatin activity [264]. Further to this, miR-
34a expression was downregulated by oxaliplatin in CRC cells,
which was associated with oxaliplatin resistance [265]. Interest-
ingly, the new and orally applicable Pt(IV) drug candidate satra-
platin induced expression of the tumor suppressor miR-34a in CRC
cells and, thus, may overcome platinum resistance [265]. However,
another study reported of oxaliplatin-induced p53 activation and
miR-34a upregulation in CRC cells, which was accompanied by
downregulation of E2F1, DUT-N, and genes of the thymidylate
biosynthesis leading to reduced dTTP levels [266]. Repression of the
tumor suppressor let-7 family by LIN28B reduced oxaliplatin ac-
tivity in CRC cells (HCT-116, SW480) as well [267]. Expression of
miR-133a increased oxaliplatin-induced apoptosis in CRC cells by
suppression of RFFL (ring ﬁnger and FYVE-like domain containing
E3-ubiquitin protein ligase) [268]. Oxaliplatin activity was also
increased by miR-139-5p via suppression of anti-apoptotic Bcl-2
protein expression [269]. Oxaliplatin-resistant CRC cells were
sensitized to oxaliplatin treatment by increased miR-297 levels,
which reduced the levels of the platinum-resistance associated
MRP2 (MDR-associated protein 2) protein in the CRC cells [270].
Expression of miR-1915 sensitized oxaliplatin-resistant CRC cells
(HCT-116/L-OHP) to oxaliplatin treatment by downregulation of
anti-apoptotic Bcl-2 protein expression [271]. In addition, expres-
sion of miR-1915 andmiR-1914* increased the activity of oxaliplatinian cancers.
, miR-181-5p, miR-193b*, miR-200c(!), miR-214, RNU2-1f (miR-1246, miR-1290)
ancer active platinum complexes and non-coding RNAs/microRNAs,
0.001
Table 11
MicroRNA tumor suppressors and oncogenes correlated with carboplatin activity in lung cancers.
Tumor suppressors Oncogenes
miR-135a*, miR-146a, miR-196b, miR-218, miR-1290 miR-19b, miR-21, miR-27a, miR-205
Table 12
MicroRNA tumor suppressors and oncogenes correlated with carboplatin activity in miscellaneous cancers.
Tumor suppressors Oncogenes
miR-34a (RB), miR-218 (CC), miR-621 (breast cancer) miR-27b (HCC), miR-146a (HCC), miR-146b-5p (HCC), miR-181a (HCC), miR-181d (HCC)
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[272].
Rectal cancer patients who responded well to oxaliplatin-
capecitabine radiochemotherapy (i.e., who showed complete
response) exhibited upregulated miR-622 and miR-630 expression
[273]. In addition, patients suffering from metastatic CRC showed
better responses to XELOX therapy (combination of capecitabine/
xeloda and oxaliplatin) and longer progression-free survival in case
of high miR-126 levels [274]. Overexpression of miR-107 and miR-
99a-3p was associated with improved outcome in patients with
metastatic CRC treated with 5-FU and oxaliplatin [275]. Advanced
CRC patients with low miR-148a expression showed poorer sur-
vival and worse response to oxaliplatin treatment [276]. In addi-
tion, patients suffering from KRAS-mutated CRC with increased
miR-200b and reduced miR-146 levels exhibited longer survival
times after treatment with oxaliplatin in combination with cape-
citabine and the antibody cetuximab [277]. Upregulation of miR-
196b-5p and miR-592 also increased the potency of the XELOX
regimen in metastatic CRC patients [278]. In contrast to that,
upregulated expression of ﬁve serum miRNAs (miR-20a, miR-130,
miR-145, miR-216, miR-372) was observed from oxaliplatin-
resistant CRC patients [279]. However, upregulated miR-143 and
miR-145 enhanced activity of oxaliplatin in CRC cells by suppres-
sion of CD44 (cluster of differentiation 44), KRAS, KLF5 (Krüppel-
like factor 5) and BRAF (v-Raf murine sarcoma viral oncogene ho-
molog B1) [280]. In addition, higher expression of miR-106a, miR-
130b and miR-484 was determined in patients with oxaliplatin-
resistant CRC when compared with responders [281]. Increased
expression of miR-320e also led to worse outcome in advanced CRC
patients who received oxaliplatin treatment [282]. Further to this,
overexpression of miR-27b, miR-181b, and miR-625-3p was
discovered in non-responding metastatic CRC patients after treat-
ment with oxaliplatin (XELOX or FOLFOX) and these three onco-
genic miRNAs were also upregulated in oxaliplatin-resistant CRC
cells (HCT-116/oxPt) [283]. A list of miRNAs involved in oxaliplatin
activity in colon cancers is given in Table 13.
2.3.2. Oxaliplatin, miRNAs, esophageal and gastric cancers
In addition to CRC, oxaliplatin has also found entrance to the
treatment of other solid cancers that are hard to tackle such as
esophageal cancer or gastric cancer. Pathologic complete response
(pCR) to chemoradiation including 5-FU (5-ﬂuorouracil) andTable 13
MicroRNA tumor suppressors and oncogenes correlated with oxaliplatin activity in color
Tumor suppressors Oncogen
let-7 family, miR-34a, miR-99a-3p, miR-107, miR-126, miR-133a,
miR-139-5p, miR-143, miR-145(!), miR-148a, miR-196b-5p, miR-200b,
miR-297, miR-592, miR-622, miR-630, miR-1914*, miR-1915
miR-20a
miR-146
miR-372
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reduced expression of miR-99b, miR-145*, miR-451, and miR-505*
in patients suffering from esophageal adenocarcinoma (EAC)
[158]. MiRNA polymorphisms also play a role for oxaliplatin resis-
tance and reduced survival of esophageal squamous cell carcinoma
(ESCC) patients receiving platinum-based therapy (cisplatin or
oxaliplatin) were correlated to the TT genotypes of miR-196a2
rs11614913 and miR-125a rs12976445 [162].
The oncogenes miR-21 and miR-181b were strongly expressed
in advanced gastric cancer tissues (GC), and advanced GC patients
with suppressed expression of miR-21 and miR-181b exhibited
better response to oxaliplatin and prolonged survival [284]. In
addition, metastatic or recurrent GC patients with high levels of
miR-1 and miR-27a showed lower response rates and shorter
overall survival after 5-FU/oxaliplatin chemotherapy [285]. Another
study reported of suppression of miR-20b, miR-27a, and miR-181a
accompanied by increased expression of MDR1, HIF1A (hypoxia-
inducible factor 1-alpha) and HIPK2 (homeodomain-interacting
protein kinase 2) in GC patients with progressing disease when
compared with responders to EOX chemotherapy (epirubicin,
oxaliplatin, capecitabine) [286]. In addition, patients suffering from
advanced GC revealed better responses to oxaliplatin treatment
when themiR-129 expression level was low [287]. GC patients who
received palliative chemotherapy (5-FU in combination with plat-
inum complexes, cisplatin or oxaliplatin) showed shorter time to
progression in association with overexpression of ﬁve miRNAs
(miR-150, miR-342-3p, miR-181b, miR-221, miR-224) and sup-
pression of miR-520 h, while shorter overall survival was associated
with increased expression of miR-150, miR-192, miR-224, miR-375,
and miR-342-3p [288]. A list of miRNAs involved in oxaliplatin
activity in esophageal and gastric cancers is given in Table 14.
2.3.3. Oxaliplatin, miRNAs and miscellaneous cancers
The combination of gemcitabine and oxaliplatin showed only
slight beneﬁts in hepatocellular carcinoma (HCC) patients. UCP2
(mitochondrial uncoupling protein 2) expression in HCC patients
was identiﬁed as resistance factor for chemotherapy in HCC pa-
tients, while induced expression of miR-214 reduced the UCP2
levels in HCC and inhibited HCC growth [289]. In contrast to that,
expression of miR-93 increased oxaliplatin resistance in hepatoma
cells by suppression of PTEN [290]. In oxaliplatin-resistant
pancreatic cancer cells (AsPc-10R), the expression of miR-21 andectal cancers.
es
, miR-21, miR-27b, miR-92a, miR-93, miR-106a, miR-130, miR-130b, miR-145(!),
, miR-153, miR-181b, miR-191, miR-197, miR-203, miR-216, miR-222, miR-320e,
, miR-484, miR-625-3p, miR-1826
ancer active platinum complexes and non-coding RNAs/microRNAs,
10.001
Table 14
MicroRNA tumor suppressors and oncogenes correlated with oxaliplatin activity in esophageal and gastric cancers.
Tumor suppressors Oncogenes
Esophageal cancer e miR-99b, miR-125a rs12976445, miR-145*, miR-196a2 rs11614913, miR-451, miR-505*
Gastric cancer miR-20b, miR-27a(!), miR-181a,
miR-520 h
miR-1, miR-21, miR-27a(!), miR-129, miR-150, miR-181b, miR-192, miR-221, miR-224, miR-342-3p, miR-375
Table 15
MicroRNAs (tumor suppressors and oncogenes) correlated with platinum activity in several cancers.
Tumor suppressors Oncogenes Tumor suppressors/Oncogenes
(depending on cancer type)
let-7c, let-7g, let-7i, miR-16, miR-20b, miR-29b, miR-30d,
miR-34a, miR-107, miR-196b, miR-218, miR-497, miR-503
miR-10a, miR-21, miR-24, miR-99b, miR-106a,
miR-125b, miR-150, miR-191, miR-192,
miR-214, miR-221, miR-222, miR-224,
miR-374a, miR-425
miR-27a, miR-31, miR-93, miR-98, miR-101, miR-128,
miR-130, miR-133a, miR-138, miR-141, miR-145,
miR-146a, miR-155, miR-181a, miR-199a, miR-200,
miR-203, miR-205, miR-375, miR-429, miR-451,
miR-630, miR-638, miR-642, miR-1290
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suppression of PTEN, PDCD4, Maspin and TPM1 (tropomyosin 1)
[291].
2.4. MiRNAs modulated in various platinum-sensitive and resistant
cancers as drugs or drug targets
The expression of certain miRNAs was modulated in various
platinum-resistant or platinum-treated cancers and, thus, these
miRNAs feature suitable drug targets (Table 15). Concerning tumor
suppressor miRNAs, tumors expressing let-7 family miRNAs (let-7c,
let-7g, let-7i), miR-16, miR-20b, miR-29b, miR-30d, miR-34a, miR-
107, miR-196b, miR-218, miR-497, and miR-503 were often associ-
ated with enhanced platinum sensitivity. Hence, treatment of
resistant tumors with these miRNAs or suitable mimics likely in-
crease platinum anticancer activity. In addition, certain oncogenic
miRNAs are involved in various platinum-resistant cancers, such as
miR-10a, miR-21, miR-24, miR-99b, miR-106a, miR-125b, miR-150,
miR-191, miR-192, miR-214, miR-221, miR-222, miR-224, miR-374a,
and miR-425. The inhibition of these oncomirs by potent miRNA
antagonists (antagomirs) represents another target for improved
platinum-based chemotherapy. Numerous miRNAs such as miR-
27a, miR-31, miR-93, miR-98, miR-101, miR-128, miR-130, miR-
133a, miR-138, miR-141, miR-145, miR-146a, miR-155, miR-181a,
miR-199a, miR-203, miR-205, miR-375, miR-429, miR-451, miR-
630, miR-638, miR-642, miR-1290 and members of the miR-200
family are either tumor suppressors or oncomirs depending on
the cancer type.
The quick and facile degradation of RNA molecules as well as
their low cell permeability limited the application of accurate
miRNAs (either mimics or antagomirs) for anticancer therapy. The
liposomal formulation MRX34 of a tumor suppressor miRNA-34a
mimic (Mirnarx Therapeutics) showed adequate stability and cell
delivery of the applied miRNA-34a mimic and led to the initiation
of phase I clinical trials with MRX34 [292]. Since miR-34a
augmented the anticancer activity of cisplatin, carboplatin and
oxaliplatin, the combination of MRX34 with platinum complexes
appears to be promising for future clinical trials of various solid
tumor diseases. Further to this, an increased lipophilicity of RNA
molecules was generated by modiﬁcationwith locked nucleic acids
(LNA). LNAs possess a methylene bridge between the 2’-oxygen and
the 4’-carbon of the ribose moiety and a prominent example of an
LNA-modiﬁed antagomir is Miravirsen (developed by Santaris
Pharma), which targets miR-122 expressed in the human liver
[292]. In addition, several dietary factors and natural products that
are easily obtained from natural sources provide a rich supply ofPlease cite this article in press as: B. Biersack, Interactions between antic
Non-coding RNA Research (2016), http://dx.doi.org/10.1016/j.ncrna.2016.1low-cost, safe and easily available miRNA-modulators for the
improvement of platinum-based chemotherapy [29,293].
3. Conclusions
The approved anticancer Pt(II) complexes cisplatin, carboplatin
and oxaliplatin modulated the miRNA proﬁle of various solid tu-
mors. Vice versa, several miRNAs were identiﬁed that inﬂuenced
platinum activity either positively or negatively. Since intrinsic or
acquired platinum resistance as well as toxic side-effects of the
cytotoxic platinum complexes are regulated bymiRNAs, a profound
knowledge of the interactions between anticancer active platinum
complexes and miRNAs is of high importance. A better under-
standing of the roles of miRNAs for the activity of platinum com-
plexes will certainly lead to improved anticancer therapy regimens
based on platinum compounds, and to better survival rates and
prognoses due to the circumvention of platinum resistance and the
improvement of patient life quality.
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